Clinical TrialMay 21, 2026, 05:52 PM
Perspective Therapeutics: VMT01 Shows 29% Response in Melanoma Study
AI Summary
Perspective Therapeutics announced positive updates on all three of its clinical programs, [²¹²Pb]VMT-α-NET, [²¹²Pb]VMT01, and [²¹²Pb]PSV359, which will be presented at the 2026 ASCO Annual Meeting. The [²¹²Pb]VMT01 melanoma study observed a new responder, bringing the total to two confirmed responses out of seven treated patients (29%) in the monotherapy cohort, with 86% showing stable disease or partial response. Updated data for [²¹²Pb]VMT-α-NET in neuroendocrine tumors showed continued deepening of responses and 72% of patients without progression, while [²¹²Pb]PSV359 advanced to Cohort 3 for solid tumors, with all programs demonstrating good tolerability.
Key Highlights
- One new responder observed in [212Pb]VMT01 3.0 mCi monotherapy cohort, totaling 2 of 7 (29%) in melanoma study.
- Six of seven patients (86%) in [212Pb]VMT01 monotherapy cohort experienced stable disease or partial response.
- Updated [212Pb]VMT-α-NET data showed 18 of 25 patients (72%) without progression and remained alive.
- Ten of 23 patients (43%) in [212Pb]VMT-α-NET Cohort 2 showed response in neuroendocrine tumors.
- [212Pb]PSV359 advanced to Cohort 3 (6.0 mCi) in Phase 1/2a study for FAP-expressing solid tumors.
- All three clinical programs were well-tolerated with no dose-limiting toxicities (DLTs) reported.
- Further data for all three programs are expected in late 2026.
Price Impact
More from CATX